報價延遲最少15分鐘:2025/02/23 09:06 EST
|
|
|
|
|
||||||||||||
|
|
|
|
|
25.34 
|
|
|
| 價值評估 |
|
盈利(現時/預測)
-1.16/3.44
|
|
企業價值
7.08B
|
| 資產負債 |
|
每股賬面淨值
33.47
|
| 現金流量 |
|
現金流量率
0.07
|
| 損益表 |
|
收益
4.66B
|
|
每股收益
34.11
|
|
同行比較
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
報價延遲最少15分鐘：2025/02/23 09:06 EST
同行比較之報價最少15分鐘延遲
|
業務概覽
|
|||
| Perrigo is one of the largest consumer health companies in the world. Since 2018, Perrigo divested its animal health and generic pharmaceuticals businesses to solely focus on consumer self-care. In North America (two thirds of total sales), the firm's product mix is anchored in private-label consumer health goods, which are sold to major retailers like Walmart, Amazon, Costco, and CVS. Perrigo also plays in Europe, Australia, and parts of Asia where it primarily generates revenue through its national brands, including Compeed, Solpadeine, Coldrex, and ellaOne. |